InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,495.72
(
0.16%
)
US TECH 100
19,390.00
(
-0.09%
)
Dow Jones
38,891.50
(
0.15%
)
Brent Oil
85.14
(
0.53%
)
Bitcoin
64,807.95
(
-0.25%
)
Post# of 252259
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 119875
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jbog post# 96997

Tuesday, 04/26/2011 6:44:55 PM

Tuesday, April 26, 2011 6:44:55 PM

Post# of 252259
REGN/SNY—Aflibercept (VEGF-Trap) shows statsig OS benefit in second-line colorectal cancer:

http://finance.yahoo.com/news/Sanofiaventis-and-Regeneron-prnews-2623348696.html?x=0&.v=1

The phase-3 VELOUR study tested FOLFIRI ± aflibercept in patients who had progressed on FOLFOX in the first-line setting. Details will be presented at an unspecified medical meeting. (It may be too late for ASCO.)

The new brand name for aflibercept in cancer is Zaltrap.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up